POLICY BULLETIN

PDF

What is new/changed?

Technical amendments to Commissioner's Directives 566-10 - Urinalysis Testing in Institutions and 566-11 - Urinalysis Testing in the Community.

Why was the policy changed?

The policy was changed as a result of enhancements in the science of screening processes, thus providing better means in detecting illegal substances.

The annexes of both CDs 566-10 and 566-11 were amended due to changes to the list of drugs tested and revisions to the cut-off levels for the screening tests and confirmation tests for certain classes of intoxicants. These cut-off levels reflect more stringent testing procedures to more fully and completely capture the presence of substance. One substance was removed from the benzodiazepine list (halazepam) because it is not applicable to CSC. Two substances were added (bromazepam and flurazepam).

Changes were made to the screening and confirmation values in the Dilute specimens to reflect improvements in the testing methodology (amphetamine, cannabinoids, cocaine and phencyclidine).

How was it developed?

The need for the technical amendments was highlighted following a review of the policy by the Security Branch at National Headquarters.

Accountability?

Institutional Heads are responsible for ensuring compliance.

Who will be affected by the policy?

CSC staff involved in urinalysis testing in institutions.

Expected cost?

No cost.

Other impacts?

None.

Table of Contents